US5897871AExpiredUtility

Therapeutic agent for the treatment of melanomas

72
Assignee: BETATINE LIMITEDPriority: Mar 22, 1993Filed: Aug 7, 1997Granted: Apr 27, 1999
Est. expiryMar 22, 2013(expired)· nominal 20-yr term from priority
Inventors:Lance Elliott Schlipalius
A61P 35/00A61K 31/015A61K 9/1075A61K 9/1274A61P 17/00
72
PatentIndex Score
32
Cited by
15
References
33
Claims

Abstract

The present invention provides a therapeutic agent for the treatment of a melanoma or melanomas by injection or intravenously including a mixture of: (a) a water soluble dispersible component; (b) an emulsifier component; and (c) a water insoluble carotenoid component in a suitable carrier medium.

Claims

exact text as granted — not AI-modified
The claims defining the invention are as follows: 
     
       1. A therapeutic composition for the treatment of a melanoma or melanomas comprising: (a) a water soluble or dispersible component;   (b) an emulsifier component;   (c) a water insoluble carotenoid component in a suitable carrier medium.   
     
     
       2. A therapeutic composition according to claim 1 wherein the water soluble or dispersible component is in the range of 30% to 90% by weight. 
     
     
       3. A therapeutic composition according to claim 1, wherein the water soluble or dispersible component is selected from the group consisting of sugar alcohols, sugars, amino acids, water, vitamins, blood serum, blood plasma, lymph, buffers, mineral salts, and combinations thereof. 
     
     
       4. A therapeutic composition according to claim 3 wherein the sugar alcohol is glycerol. 
     
     
       5. A therapeutic composition according to claim 4, wherein the glycerol is in the range of 30% to 90% by weight. 
     
     
       6. A therapeutic composition according to claim 1, wherein the emulsifier component is in the range of 0.2% to 20% by weight. 
     
     
       7. A therapeutic composition according to claim 1, wherein the emulsifier component is in the range of 1.0% to 10% by weight. 
     
     
       8. A therapeutic composition according to claim 1, wherein the emulsifier component is selected from the group consisting of glycerides, polyglycerol esters, lecithins, and other phospholipids. 
     
     
       9. A therapeutic composition according to claim 8, wherein the glyceride is glyceryl mono-oleate. 
     
     
       10. A therapeutic composition according to claim 1, wherein the water insoluble carotenoid component is predominantly beta-carotene. 
     
     
       11. A therapeutic composition according to claim 1, wherein the water insoluble carotenoid component in a suitable carrier medium comprises 2% to 50% by weight beta-carotene in a soya bean oil medium. 
     
     
       12. A therapeutic composition according to claim 1, wherein the water insoluble carotenoid component in a suitable carrier medium comprises 20% to 40% by weight beta-carotene in a soya bean oil medium. 
     
     
       13. A therapeutic composition according to claim 1, wherein the water insoluble carotenoid component in a suitable carrier medium comprises 30% by weight beta-carotene in a soya bean oil medium. 
     
     
       14. A therapeutic composition according to claim 10, wherein the beta-carotene comprises a mixture of cis beta-carotene and all trans beta-carotene. 
     
     
       15. A therapeutic composition according to claim 14, wherein the cis beta-carotene content of the beta-carotene is in the range of 50% and 90%. 
     
     
       16. A therapeutic composition according to claim 14, wherein the cis beta-carotene content of the beta-carotene is in the range of 70% and 85%. 
     
     
       17. A therapeutic composition according to claim 14, wherein the cis beta-carotene content is predominantly 9 cis beta-carotene. 
     
     
       18. A therapeutic composition according to claim 14, wherein the cis beta-carotene content is in the range of 50% and 90% 9 cis beta-carotene. 
     
     
       19. A therapeutic composition according to claim 1, wherein the water insoluble carotenoid component is in the range of 0.1% to 10% by weight of the composition. 
     
     
       20. A therapeutic composition according to claim 1, wherein the water insoluble carotenoid component is in the range of 1% to 5% by weight of the composition. 
     
     
       21. A therapeutic composition according to claim 1, wherein the carrier medium used to carry the water insoluble carotenoid component is selected from the group consisting of fatty acids, triglyceride lipids, non-saponifiable lipids, petroleum hydrocarbons, and combinations thereof. 
     
     
       22. A therapeutic composition according to claim 21, wherein the triglyceride lipids are selected from the group consisting of fats and/or oils derived from plant sources and from animal sources. 
     
     
       23. A therapeutic composition according to claim 1, wherein the carrier medium is in the range of 1% to 40% by weight of the composition. 
     
     
       24. A therapeutic composition according to claim 1, wherein the carrier medium is in the range of 1% to 20% by weight of the composition. 
     
     
       25. A therapeutic composition according to claim 1, wherein the composition is diluted for direct introduction into the bloodstream or tissue. 
     
     
       26. A therapeutic composition according to claim 25, wherein the agent is diluted by aqueous buffers, normal intravenous preparations, isotonic saline, 5% dextrose solution, blood serum or combinations thereof. 
     
     
       27. A method of treatment of a melanoma or melanomas comprising introducing directly into the bloodstream or melanoma an effective amount of a therapeutic composition according to claim 1. 
     
     
       28. The method of treatment of melanoma or melanomas according to claim 27, wherein the effective amount is from 0.1 to 10.0 micrograms/ml of the therapeutic composition contacting the melanoma cells. 
     
     
       29. The method of treatment of melanoma or melanomas according to claim 27, wherein the effective amount is from 0.1 to 3.0 micrograms/ml of the therapeutic composition contacting the melanoma cells. 
     
     
       30. A method of treatment of melanoma or melanomas according to claim 27, wherein the introduction of the therapeutic composition into the bloodstream is by injection or intravenously. 
     
     
       31. A method of treatment of a melanoma or melanomas according to claim 27, wherein the introduction of the therapeutic agent directly into the site of the melanoma or melanomas is by injection. 
     
     
       32. A therapeutic composition for the treatment of a melanoma or melanomas, comprising: (a) a water soluble or dispersible component;   (b) an emulsifier component; and   (c) a water insoluble carotenoid component in a suitable carrier medium, wherein said water soluble or dispersible component is in the range of 30% to 90% by weight.     
     
     
       33. A method of treatment of melanoma or melanomas comprising the step of introducing directly into the bloodstream or melanoma an effective amount of a therapeutic composition according to claim 32.

Join the waitlist — get patent alerts

Track US5897871A — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.